CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT03628716 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer

Interventions

BIOLOGICAL: CV301
BIOLOGICAL: Atezolizumab

Sponsor

Bavarian Nordic